04.06.2013 - Active Biotech's immunotoxin naptumomab estafenatox has doubled overall survival in renal cell cancer patients.
A combination therapy of Active Biotech's fusion protein naptumomab estafenatox (ABR-217620), plus interferon-alpha, extended overall survival in a patient subgroup of the ANYARA Phase II/III study to 63.3 compared to 31.1 months in the interferon-alpha arm. The drug is a new class of fusion protein, which links a FAB fragment of an antibody that specifically binds to the 5T4 antigen on tumour cells with the superantigen staphylococcal enterotoxin, that induces a tumour-specific T-cell immune response.
Statistically significant benefit, however, was only achieved when patients with high levels of pre-formed antibodies against superantigens or the cytokine IL-6 were excluded. In this subgroup of 131 patients, progression-free survival improved from 5.8 months in the interferon-alpha arm to 8.5 months in the naptumomab estafenatox - interferon-alpha arm. Active Biotech is now seeking a partner for Phase III development of the targeted cancer therapy"
Renal Cell Carcinoma (RCC) affects approximately 180,000 people worldwide each year. Approximately 50 % of the patients are affected by metastases. If the disease has metastasized, average survival is around 2 years. The survival rate of patients diagnosed with renal cancer is only 5-15% after five years. The market for treatment of RCC is estimated at approximately US$2.7bn per year (EvaluatePharma March 2012). Approved first-line treatments are Sutent, Avastin in combination with IFN, Torisel and Votrient. Authorised second-line treatment are Nexavar and Everolimus.
26.05.2016 BigDNA relaunches as Iceni Pharmaceuticals with the aim to develop repurposed and reformulated cancer therapies. First order of business: repurpose Merck Serono’s cilengitide as a multiple myeloma treatment.
24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.
20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.
18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.
11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.
09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.
04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.
03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.